We also investigated the role of angiogenesis in CD47 blockade therapy, and we further explored whether combining CD47 blockade with anti-angiogenic drugs could deliver a stronger anti-tumor effect in bladder cancer. This evidence concerns the gene CD47 and urinary bladder carcinoma.